Iovance Biotherapeutics Inc. (NASDAQ:$IOVA) is a huge mover this week as shares have increased 5.10%, or $0.4 during the last trading session. In total, about 568,977 shares have been traded, 39.85% up from the average.
The company is a clinical-stage biopharmaceutical company, focusing on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Currently, Iovance is reported negative earnings. The market cap is set at $517.16 million.
Wall Street patiently awaits Iovance’s earnings release on November 3rd, with forecasted EPS to be $-0.35, down exactly $0.03 or 9.37% from 2014’s $-0.32 EPS.
Featured Image: Depositphotos/© Ai825
